Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2017
At a glance
- Drugs Edoxaban (Primary)
- Indications Atrial fibrillation
- Focus Pharmacodynamics; Pharmacokinetics; Registrational
- Sponsors Daiichi Sankyo Inc
- 24 Oct 2017 This study has been completed in Denmark, according to European Clinical Trials Database record.
- 11 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated